SEARCH:   Advanced

Blood, 21 May 2009, Vol. 113, No. 21, pp. 5090-5093. Prepublished online as a Blood First Edition Paper on March 16, 2009; DOI 10.1182/blood-2008-12-194704. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-12-194704v1 113/21/5090    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Renneville, A. Articles by Dombret, H. Search for Related Content PubMed PubMed Citation Articles by Renneville, A. Articles by Dombret, H. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 15, 2008 Accepted March 6, 2009 The favorable impact of CEBPA mutations in patients with acute myeloid leukemia (AML) is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD) Aline Renneville, Nicolas Boissel, Nathalie Gachard, Dina Naguib, Christian Bastard, Stephane de Botton, Olivier Nibourel, Cecile Pautas, Oumedaly Reman, Xavier Thomas, Claude Gardin, Christine Terre, Sylvie Castaigne, Claude Preudhomme, and Herve Dombret* Department of Hematology, Hopital Claude Huriez, Lille, France Department of Hematology, Hopital Saint-Louis, AP-HP and EA3518 University Paris 7, Paris, France Department of Hematology, Centre Hospitalier Universitaire Dupuytren, Limoges, France Department of Hematology, Centre Hospitalier Universitaire, Caen, France Department of Hematology, Centre Henri Becquerel, Rouen, France Department of Hematology, Institut Gustave Roussy, Villejuif, France Department of Hematology, Hopital Henri Mondor, AP-HP, Creteil, France Department of Hematology, Hopital Edouard Herriot, Lyon, France Department of Hematology, Hopital Avicenne, AP-HP, Bobigny, France Department of Hematology, Hopital Mignot, Versailles, France * Corresponding author; email: herve.dombret{at}sls.aphp.fr. Mutations of the CEBPA gene have been associated with a favorable outcome in patients with AML, but mainly in those with a normal karyotype. Here, we analyzed the impact of associated cytogenetic abnormalities or bad-prognosis FLT3-ITD in 53 patients with CEBPA+ de novo AML treated in the ALFA trials. We found that only those with a normal karyotype and no FLT3-ITD displayed the expected favorable outcome. In this context, relapse-free, disease-free, and overall survival were significantly longer than in corresponding patients without CEBPA mutation (P=0.035, 0.016, and 0.047 respectively). This was not observed in the context of an abnormal karyotype or associated FLT3-ITD. Furthermore, after adjustment on age, trial, and mutation type, these features were independently predictive of shorter overall survival in the subset of patients with CEBPA+ AML (multivariate hazard ratio=2.7 [95% CI, 1.08-6.7] and 2.9 [95% CI, 1.01-8.2] with P=0.034 and 0.05, for abnormal karyotype and FLT3-ITD, respectively). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. B. Micol, N. Boissel, A. Renneville, S. Castaigne, C. Gardin, C. Preudhomme, and H. Dombret The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication Blood, November 12, 2009; 114(20): 4601 - 4602. [Full Text] [PDF] I. H. I. M. Hollink, M. M. van den Heuvel-Eibrink, and C. M. Zwaan CEBPA resembles Roman god Janus Blood, June 25, 2009; 113(26): 6501 - 6502. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020